Beovu is out and finally we have some very preliminary patient results to share. I recently wrote about why Beovu would potentially be superior to what we have available – ARTICLE.
There is a higher molar dose of anti-VEGF delivered with Beovu and a smaller molecular size which might have better retinal penetration. Lastly in the study, there was an observed better drying effect over Eylea (aflibercept) in the first few months of the study.
Trying to determine which patients are right for the drug was my first question. I’ve had patients with success on agents now some of which I’ve extended to 10 or 12 weeks. However, I do have many patients that I cannot extend beyond 4-8 weeks for which I thought this drug would be perfect for.
Here are a couple of case examples. Please note this is a noncomparative series and individual cases so to make sweeping conclusions is not possible.
Overall, I am quite impressed with the amount of fluid reduction I am seeing which I would rate at or better than what I observed with Eylea (aflibercept). There are no signs of adverse events thus far on the handful of patients I have treated. Looking forward to seeing more patients return to better assess the response.